Pharming PHAR
NASDAQ PHAR
$9.75 -0.20 (-2.01%)
At close: Oct 2, 2026 · 4:00 PM EDT

Pharming (PHAR) Non Operating Investment Income (2025 - 2026)

Updated

Pharming's Non Operating Investment Income came in at $26.15 million for Q2 2026, compared with -$17.82 million a year earlier.

Analysis

Pharming (PHAR) Non Operating Investment Income (2025 - 2026) Analysis & Trends

Over the trailing twelve months to Jun 30, 2026, Pharming reported Non Operating Investment Income of -$22.65 million.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Op. Investment Inc. (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn -
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn -
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn -
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn -
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn -
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn -
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn -
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn -
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn -
10 Pharming 684.14 Mn -146.02 Mn 141.47 Mn 26.15 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 26.15 Mn
Mar 31, 2026 -14.72 Mn
Sep 30, 2025 -16.26 Mn
Jun 30, 2025 -17.82 Mn
API Access

Pharming Non Operating Investment Income API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-operating-investment-income&ticker=PHAR&period=max&api_key=YOUR_API_KEY